KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT: 2019-2024

Historic EBT for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Dec 2024 value amounting to -$547.5 million.

  • Ginkgo Bioworks Holdings' EBT fell 42.23% to -$80.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.1 million, marking a year-over-year increase of 47.81%. This contributed to the annual value of -$547.5 million for FY2024, which is 38.68% up from last year.
  • Latest data reveals that Ginkgo Bioworks Holdings reported EBT of -$547.5 million as of FY2024, which was up 38.68% from -$892.9 million recorded in FY2023.
  • Ginkgo Bioworks Holdings' 5-year EBT high stood at -$124.8 million for FY2020, and its period low was -$2.1 billion during FY2022.
  • For the 3-year period, Ginkgo Bioworks Holdings' EBT averaged around -$1.2 billion, with its median value being -$892.9 million (2023).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 1,372.45% in 2021, then surged by 57.91% in 2023.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBT (Yearly) stood at -$124.8 million in 2020, then slumped by 1,372.45% to -$1.8 billion in 2021, then declined by 15.41% to -$2.1 billion in 2022, then skyrocketed by 57.91% to -$892.9 million in 2023, then soared by 38.68% to -$547.5 million in 2024.